Abstract 1868P
Background
Patients with incurable cancer often face difficult decisions about their care. Shared decision making (SDM) can help people make the decisions that are right for them, by supporting understanding and ensuring their priorities are considered. Essential for this is health literacy (HL) - the personal competencies and situational resources needed for people to process information to make decisions. This study sought to understand the barriers to SDM in the context of HL from the perspective of patients and clinicians, and consider how they may be overcome.
Methods
This mixed methods study comprised: 1) semi-structured interviews with patients with incurable cancer and suspected HL difficulties, identified by clinicians from 2 district hospitals; and 2) an online survey of NHS healthcare professionals caring for patients with incurable cancer. Interview data were analysed using the Framework Approach to identify important and recurrent themes. For the survey, a descriptive analysis was carried out for the quantitative data, and thematic analysis for the qualitative data.
Results
Twenty-one interviews were conducted. Patients had a range of diagnoses and had received various treatments. Themes related to experiences (supportive staff in an imperfect system, additional pressure from COVID-19, in the expert’s hands, treatment not so bad) and barriers to SDM (emotional hurdles, accessing and understanding information, wanting to be a good patient). Survey participants (N=70) included doctors, nurses, and a pharmacist. Views towards SDM ranged from those who aim to ‘always’ use it, to those who feel its use should be limited. Patient, clinician, and situational barriers were identified. Key challenges for SDM include the persistence of paternalistic clinician-patient roles, dealing with emotional hurdles, and practical issues.
Conclusions
There are socio-cultural, emotional and system barriers to SDM in incurable cancer for those with HL difficulties. Addressing this combination of issues will be important to fully embed its use in practice. Recommendations to improve SDM range from large scale policy changes to provision of easily accessible and understandable patient information and decision aids in a variety of formats.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Southampton.
Funding
Robert White Legacy Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05